Summary
Signal counts
Assets tracked: 5
Watchlist assets: 4
Registry stop assets: 0
Sponsor overview
Qilu Pharmaceutical Co., .
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07102004 | https://clinicaltrials.gov/study/NCT05652855 | https://clinicaltrials.gov/study/NCT07198633 | https://clinicaltrials.gov/study/NCT06911827 | https://clinicaltrials.gov/study/NCT07453394 | https://clinicaltrials.gov/study/NCT07061639
Assets
Linked programs
- MHB088C for Injection: Watchlist Signal (2/5)
- QLC5508: Operational Burden Signal (2/5)
- QLP2117: Low Signal (1/5)
- QLS5132; Bevacizumab: Operational Burden Signal (2/5)
- QLS5133: Operational Burden Signal (2/5)